Marshall Wace LLP Buys 1,032,070 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Marshall Wace LLP lifted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 139.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,773,246 shares of the medical technology company's stock after buying an additional 1,032,070 shares during the quarter. Marshall Wace LLP owned 1.25% of Alphatec worth $16,278,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ATEC. HighTower Advisors LLC increased its holdings in Alphatec by 16.2% in the third quarter. HighTower Advisors LLC now owns 52,232 shares of the medical technology company's stock valued at $290,000 after buying an additional 7,299 shares during the last quarter. Stifel Financial Corp boosted its position in shares of Alphatec by 19.7% in the third quarter. Stifel Financial Corp now owns 178,702 shares of the medical technology company's stock worth $994,000 after buying an additional 29,411 shares during the period. State Street Corp increased its holdings in shares of Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock valued at $17,453,000 after purchasing an additional 287,350 shares during the period. XTX Topco Ltd purchased a new stake in shares of Alphatec during the third quarter worth $69,000. Finally, Barclays PLC lifted its stake in Alphatec by 362.3% in the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after acquiring an additional 133,653 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ATEC has been the topic of a number of analyst reports. Barclays increased their price objective on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, January 22nd. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Piper Sandler raised their target price on shares of Alphatec from $12.00 to $13.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Finally, Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $17.67.

Alphatec Price Performance

ATEC traded up $0.19 during trading on Thursday, hitting $11.40. The company's stock had a trading volume of 1,502,008 shares, compared to its average volume of 2,049,723. The firm's 50 day moving average price is $10.39 and its two-hundred day moving average price is $9.61. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -8.91 and a beta of 1.20. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Alphatec

In related news, CEO Patrick Miles sold 12,691 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the sale, the chief executive officer now owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP David Sponsel sold 33,732 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the completion of the sale, the executive vice president now directly owns 668,977 shares of the company's stock, valued at approximately $7,245,020.91. The trade was a 4.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 272,113 shares of company stock valued at $3,121,225 over the last 90 days. 22.80% of the stock is owned by corporate insiders.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.